GI
KROS icon

GAMMA Investing’s Keros Therapeutics KROS Stock Holding History

GAMMA Investing’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.82K Buy
824
+603
+273% +$6.72K ﹤0.01% 3275
2026
Q1 		$2.44K Sell
221
-93
-30% -$1.44K ﹤0.01% 3601
2025
Q4 		$6.39K Sell
314
-47
-13% -$825 ﹤0.01% 3172
2025
Q3 		$5.71K Sell
361
-13
-3% -$192 ﹤0.01% 3123
2025
Q2 		$4.99K Buy
374
+137
+58% +$1.85K ﹤0.01% 3117
2025
Q1 		$2.42K Buy
237
+206
+665% +$2.39K ﹤0.01% 3357
2024
Q4 		$491 Sell
31
-36
-54% -$1.87K ﹤0.01% 3574
2024
Q3 		$3.89K Buy
67
+23
+52% +$1.14K ﹤0.01% 2846
2024
Q2 		$2.01K Buy
44
+2
+5% +$107 ﹤0.01% 2880
2024
Q1 		$2.78K Buy
42
+5
+14% +$296 ﹤0.01% 2637
2023
Q4 		$2.05K Buy
+37
New +$1.16K ﹤0.01% 2572

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

GAMMA Investing's KROS Position: Q2 2026 in Review

GAMMA Investing increased its Keros Therapeutics (KROS) stake by 273% in Q2 2026, buying an estimated $6.72K and bringing the position to 824 shares worth $8.82K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

GAMMA Investing first reported a position in KROS in Q4 2023 and has held it in 11 quarters since. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • GAMMA Investing held 824 shares of Keros Therapeutics worth $8.82K as of Q2 2026.
  • GAMMA Investing bought 603 Keros Therapeutics shares in Q2 2026, an estimated $6.72K.
  • Keros Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3275 holding.
  • GAMMA Investing first reported a position in Keros Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.